Periodic Safety Update Reports (PSURs) are among the most important regulatory documents used to monitor the safety of medicinal products after marketing authorisation. They provide regulators and marketing authorisation holders with a structured mechanism for reviewing accumulated safety information, assessing the benefit-risk profile of a product and determining whether changes to product information, risk minimisation activities or regulatory actions may be necessary.
For Qualified Persons Responsible for Pharmacovigilance (QPPVs), PSURs represent a key component of pharmacovigilance governance. Although specialist teams often prepare the reports, QPPVs are expected to maintain awareness of significant safety issues, important signals, benefit-risk conclusions and regulatory commitments arising from aggregate safety reporting activities.
What is a PSUR?
A Periodic Safety Update Report is a regulatory document that provides a comprehensive review of the cumulative safety experience of a medicinal product over a defined reporting interval.
Unlike individual adverse event reports that focus on specific cases, PSURs examine aggregated data and evaluate whether the overall understanding of the product's safety profile has changed.
The purpose of a PSUR is not simply to list adverse reactions. Instead, it is intended to answer a more important question:
Does the totality of available evidence continue to support a positive benefit-risk balance?
To answer this question, PSURs integrate information from multiple sources including adverse event reports, clinical studies, scientific literature, regulatory actions, signal evaluations and post-authorisation safety activities.
Why PSURs Exist
Medicinal products continue to generate new information long after initial approval.
New safety information may emerge through:
- Spontaneous adverse event reporting
- Scientific literature monitoring
- Clinical trials
- Post-authorisation safety studies
- Epidemiological investigations
- Signal detection activities
- Regulatory authority assessments
- Product quality investigations
- Risk minimisation effectiveness studies
Individual data points rarely provide a complete understanding of product safety.
PSURs allow these diverse sources of information to be reviewed collectively and interpreted within the broader context of product exposure and therapeutic benefit.
They therefore serve as an essential tool for lifecycle pharmacovigilance and continuous benefit-risk evaluation.
Regulatory Basis
Within the European Union, PSUR requirements are established through pharmacovigilance legislation and supporting regulatory guidance.
Key references include:
- Directive 2001/83/EC
- Regulation (EC) No 726/2004
- EMA Good Pharmacovigilance Practices (GVP) Module VII
- ICH E2C(R2) Periodic Benefit-Risk Evaluation Report Guideline
These frameworks define the purpose, structure, submission requirements and regulatory expectations associated with PSUR preparation.
Over time, regulatory expectations have evolved from simple safety summaries toward comprehensive benefit-risk evaluations.
PSUR versus PBRER
Many professionals encounter both the terms PSUR and PBRER.
Historically, PSURs focused primarily on summarising safety information collected during a reporting interval.
The ICH E2C(R2) guideline introduced the concept of the Periodic Benefit-Risk Evaluation Report (PBRER), which places greater emphasis on integrated assessment of both benefits and risks.
Modern PSURs are generally prepared using PBRER principles and methodologies.
In practice, organisations often continue to use the term PSUR while preparing reports that follow the structure described in ICH E2C(R2).
The PSUR Lifecycle
Preparation of a PSUR is a complex multidisciplinary activity that may require months of planning and coordination.
Typical stages include:
- Planning and scheduling
- Determination of the reporting interval
- Establishment of the data lock point
- Collection of safety data
- Exposure estimation
- Signal evaluation
- Benefit-risk assessment
- Quality review
- Medical review
- Regulatory submission
Large organisations often involve pharmacovigilance, epidemiology, biostatistics, regulatory affairs, clinical development, quality assurance and medical affairs teams throughout the process.
Data Lock Point (DLP)
The Data Lock Point represents the cut-off date for data included within the report.
All analyses, case counts, exposure estimates and assessments are generally based on information available up to this date.
Information received after the DLP is normally evaluated within subsequent reporting periods unless it represents an urgent safety concern requiring immediate regulatory action.
Accurate management of the DLP is fundamental because it defines the dataset used to support all report conclusions.
Exposure Data
A critical component of PSUR preparation involves understanding how many patients have been exposed to the medicinal product.
Without exposure information, interpretation of adverse event frequencies becomes difficult.
Exposure estimates may be derived from:
- Prescription data
- Sales data
- Patient registries
- Clinical trial databases
- Treatment course estimates
- Patient-year calculations
Exposure data provide the denominator required to place safety observations into context.
Products with extensive global exposure naturally generate more adverse event reports than products with limited utilisation.
Meaningful interpretation therefore requires understanding both event counts and exposure levels.
Signal Evaluation
Signal management plays a central role in modern PSURs.
Signals may arise from:
- Spontaneous reports
- Literature reviews
- Clinical trials
- Epidemiological studies
- Regulatory authority communications
- External scientific findings
The PSUR should describe important signals evaluated during the reporting interval and explain the rationale supporting conclusions reached.
Potential outcomes include:
- Signal closed
- Signal under evaluation
- Signal confirmed
- Product information updated
- Additional studies initiated
Signal discussions demonstrate how the pharmacovigilance system identifies and evaluates emerging safety concerns.
Benefit-Risk Assessment
The benefit-risk evaluation is often regarded as the most important section of the PSUR.
Rather than reviewing risks in isolation, this assessment considers both positive therapeutic effects and safety concerns.
Factors commonly evaluated include:
- Clinical efficacy
- Severity of treated disease
- Frequency of adverse events
- Seriousness of identified risks
- Availability of alternative therapies
- Effectiveness of risk minimisation measures
- Emerging safety findings
The objective is to determine whether the medicinal product continues to provide a favourable balance between benefits and risks.
Worldwide Regulatory Status
PSURs typically summarise significant regulatory activities occurring during the reporting interval.
These may include:
- Marketing authorisations
- Product withdrawals
- Suspensions
- Major labelling updates
- Restrictions of use
- New indications
- Safety communications
Reviewing global regulatory actions helps provide context for ongoing benefit-risk assessments.
Actions Taken for Safety Reasons
A dedicated section usually describes regulatory or company actions implemented in response to safety concerns.
Examples include:
- New warnings
- Contraindications
- Monitoring recommendations
- Additional risk minimisation measures
- Product recalls
- Educational materials
Documentation of these actions helps demonstrate ongoing management of identified risks.
Role of the QPPV
Although operational preparation is frequently delegated, the QPPV retains an important oversight role.
QPPVs should maintain awareness of:
- Significant PSUR conclusions
- Emerging safety concerns
- Important signals
- Benefit-risk assessments
- Regulatory commitments
- Submission status
- Inspection implications
Inspectors often expect QPPVs to discuss major findings arising from aggregate safety reports and explain how those findings influence pharmacovigilance governance activities.
PSURs and the PSMF
PSUR processes are closely connected to the Pharmacovigilance System Master File (PSMF).
The PSMF should describe the systems, responsibilities and procedures supporting aggregate safety reporting activities.
Inspectors may review evidence demonstrating that PSUR preparation, review, approval and submission activities operate effectively within the broader pharmacovigilance system.
Common Inspection Findings
Regulatory inspections occasionally identify deficiencies associated with PSUR processes.
Examples include:
- Late submissions
- Inadequate signal evaluations
- Weak benefit-risk assessments
- Poor traceability of conclusions
- Incomplete documentation
- Exposure estimation deficiencies
- Inadequate vendor oversight
- Lack of QPPV awareness regarding important findings
Many observations reflect systemic governance weaknesses rather than isolated reporting errors.
Practical Considerations for QPPVs
Experienced QPPVs rarely write PSURs themselves.
Instead, they focus on ensuring that:
- Appropriate procedures exist
- Responsibilities are clearly defined
- Significant safety concerns are escalated
- Governance mechanisms function effectively
- Regulatory obligations are fulfilled
- Vendors are appropriately managed
- Inspection readiness is maintained
This oversight-focused approach aligns with the broader responsibilities associated with pharmacovigilance governance.
Future Topics
The subject of PSURs is extensive and several related areas warrant detailed discussion in their own right.
Examples include:
- Exposure Estimation in PSURs
- Benefit-Risk Assessment Methodology
- Signal Evaluation within PSURs
- PSUR Submission Requirements
- PSUR Assessment Process
- Data Lock Points
- PSUR Compliance Metrics
- PSUR Inspection Findings
- PSUR versus PBRER
Each of these topics can be explored in greater depth through dedicated articles.
Conclusion
Periodic Safety Update Reports remain one of the most important regulatory tools used to monitor medicinal product safety after approval. By integrating cumulative safety information, exposure data, signal evaluations and benefit-risk assessments, PSURs provide regulators and marketing authorisation holders with a structured framework for ongoing safety oversight.
For QPPVs, PSURs are more than a submission requirement. They provide critical insight into product safety trends, emerging risks, regulatory expectations and pharmacovigilance system performance. Maintaining awareness of PSUR conclusions and ensuring appropriate governance around aggregate reporting activities is therefore a fundamental aspect of effective pharmacovigilance oversight.